Literature DB >> 9884077

Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships.

K Varani1, G Calo, A Rizzi, S Merighi, G Toth, R Guerrini, S Salvadori, P A Borea, D Regoli.   

Abstract

The present study describes the labelling of the nociceptin (NC) receptor, ORL1, in mouse forebrain membranes with a new ligand partially protected from metabolic degradation at the C-terminal; the ligand, [3H]-NC-NH2, has a specific activity of 24.5 Ci mmol(-1). Saturation experiments revealed a single class of binding sites with a KD value of 0.55 nM and Bmax of 94 fmol mg(-1) of protein. Non specific binding was 30% of total binding. Kinetic binding studies yielded the following rate constants: Kobs = 0.104 min(-1); K1 =0.034 min(-1): T1/2=20 min; K(+1)=0.07 min nM(-1). Thermodynamic analyses indicated that [3H]-NC-NH2 binding to the mouse ORL1 is totally entropy driven, similar to what has been observed for the labelled agonists to the opioid receptors OP1(delta), OP2(kappa) and OP3(mu). Receptor affinities of several NC fragments and analogues, including the newly discovered ORL-1 receptor antagonist [Phe1psi(CH2-NH)Gly2]NC(1-13)-NH2([F/G]NC(1-13)-NH2), were also evaluated in displacement experiments. The competition curves for these compounds were found to be parallel to that of NC and the following order of potency was determined for NC fragments: NC-OH = NC-NH2-NC(1-13)-NH2 > > NC(1-12)-NH2 > NC(1-13)-OH > > NC(1-11)-NH2, and for NC and NC(1-13)-NH2 analogues: [Tyr1]NC-NH2 > or = [Leu1]NC(1-13)-NH2 > or = [Tyr1]NC(1-13)-NH2 > or = [F/G]NC(1-13)-NH2 > > [Phe3]NC(1-13)-NH2 > [DF/G]NC(1-13)-NH2. Standard opioid receptor ligands (either agonists or antagonists) were unable to displace [3H]-NC-NH2 binding when applied at concentrations up to 10 microM indicating that this new radioligand interacts with a non opioid site, probably the ORL1 receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884077      PMCID: PMC1565735          DOI: 10.1038/sj.bjp.0702226

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro.

Authors:  M Connor; C W Vaughan; E A Jennings; R G Allen; M J Christie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors.

Authors:  H Okawa; B Nicol; R Bigoni; R A Hirst; G Calo; R Guerrini; D J Rowbotham; D Smart; A T McKnight; D G Lambert
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 5.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

Review 6.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

7.  Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor.

Authors:  Cristiano Nazzaro; Mario Barbieri; Katia Varani; Lorenzo Beani; Rita J Valentino; Anna Siniscalchi
Journal:  Neuropharmacology       Date:  2009-09-09       Impact factor: 5.250

8.  Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.

Authors:  Salvatore Pacifico; Alfonso Carotenuto; Diego Brancaccio; Ettore Novellino; Erika Marzola; Federica Ferrari; Maria Camilla Cerlesi; Claudio Trapella; Delia Preti; Severo Salvadori; Girolamo Calò; Remo Guerrini
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.